Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.

St Louis EK, Boeve AR, Boeve BF.

Mov Disord. 2017 May;32(5):645-658. doi: 10.1002/mds.27018. Review.

PMID:
28513079
2.

Is pure autonomic failure an early marker for Parkinson disease, dementia with Lewy bodies, and multiple system atrophy? And other updates on recent autonomic research.

Muppidi S, Miglis MG.

Clin Auton Res. 2017 Apr;27(2):71-73. doi: 10.1007/s10286-017-0408-8. Epub 2017 Mar 2. No abstract available.

PMID:
28255741
3.

Pure autonomic failure: Predictors of conversion to clinical CNS involvement.

Singer W, Berini SE, Sandroni P, Fealey RD, Coon EA, Suarez MD, Benarroch EE, Low PA.

Neurology. 2017 Mar 21;88(12):1129-1136. doi: 10.1212/WNL.0000000000003737. Epub 2017 Feb 15.

PMID:
28202694
4.

Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.

White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA.

Am J Cardiol. 2017 Apr 1;119(7):1111-1115. doi: 10.1016/j.amjcard.2016.11.066. Epub 2017 Jan 6. Review.

5.

Natural history of pure autonomic failure: A United States prospective cohort.

Kaufmann H, Norcliffe-Kaufmann L, Palma JA, Biaggioni I, Low PA, Singer W, Goldstein DS, Peltier AC, Shibao CA, Gibbons CH, Freeman R, Robertson D; Autonomic Disorders Consortium.

Ann Neurol. 2017 Feb;81(2):287-297. doi: 10.1002/ana.24877.

6.

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.

Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H.

J Neurol. 2017 Jan 3. doi: 10.1007/s00415-016-8375-x. [Epub ahead of print] Review.

PMID:
28050656
7.

Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).

Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.

J Parkinsons Dis. 2016 Oct 19;6(4):751-759.

PMID:
27636856
8.

Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.

Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB.

J Am Soc Hypertens. 2016 Oct;10(10):755-762. doi: 10.1016/j.jash.2016.07.010. Epub 2016 Aug 4.

9.

Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.

Fran├žois C, Rowse GJ, Hewitt LA, Vo P, Hauser RA.

BMC Neurol. 2016 Aug 18;16(1):143. doi: 10.1186/s12883-016-0665-5.

10.

Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Goldstein DS, Holmes C, Sullivan P, Jinsmaa Y, Kopin IJ, Sharabi Y.

Parkinsonism Relat Disord. 2016 Oct;31:79-86. doi: 10.1016/j.parkreldis.2016.07.009. Epub 2016 Jul 20.

PMID:
27474472
11.

Pure Autonomic Failure.

Thaisetthawatkul P.

Curr Neurol Neurosci Rep. 2016 Aug;16(8):74. doi: 10.1007/s11910-016-0673-2. Review.

PMID:
27338613
12.

Survival in synucleinopathies: A prospective cohort study.

Goldstein DS, Holmes C, Sharabi Y, Wu T.

Neurology. 2015 Nov 3;85(18):1554-61. doi: 10.1212/WNL.0000000000002086. Epub 2015 Oct 2.

13.

Residual sympathetic tone is associated with reduced insulin sensitivity in patients with autonomic failure.

Celedonio JE, Arnold AC, Dupont WD, Ramirez CE, Diedrich A, Okamoto LE, Raj SR, Robertson D, Peltier AC, Biaggioni I, Shibao CA.

Clin Auton Res. 2015 Oct;25(5):309-15. doi: 10.1007/s10286-015-0307-9. Epub 2015 Sep 10.

14.

Droxidopa in neurogenic orthostatic hypotension.

Kaufmann H, Norcliffe-Kaufmann L, Palma JA.

Expert Rev Cardiovasc Ther. 2015;13(8):875-91. doi: 10.1586/14779072.2015.1057504. Epub 2015 Jun 19.

15.

Multiple system atrophy: using clinical pharmacology to reveal pathophysiology.

Jordan J, Shibao C, Biaggioni I.

Clin Auton Res. 2015 Feb;25(1):53-9. doi: 10.1007/s10286-015-0271-4. Epub 2015 Mar 11.

16.

Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.

Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H; Droxidopa 302 Investigators.

Hypertension. 2015 Jan;65(1):101-7. doi: 10.1161/HYPERTENSIONAHA.114.04035. Epub 2014 Oct 27.

17.

New developments in the management of neurogenic orthostatic hypotension.

Biaggioni I.

Curr Cardiol Rep. 2014 Nov;16(11):542. doi: 10.1007/s11886-014-0542-z. Review.

PMID:
25303896
18.

Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.

Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ; NOH301 Investigators.

Neurology. 2014 Jul 22;83(4):328-35. doi: 10.1212/WNL.0000000000000615. Epub 2014 Jun 18.

19.

Quantitative indices of baroreflex-sympathoneural function: application to patients with chronic autonomic failure.

Rahman F, Goldstein DS.

Clin Auton Res. 2014 Jun;24(3):103-10. doi: 10.1007/s10286-014-0234-1. Epub 2014 Apr 5.

PMID:
24706176
20.

[Impaired exercise-induced blood pressure control in patients with Parkinson's disease and related disorders].

Deguchi K.

Rinsho Shinkeigaku. 2013;53(11):1379-81. Review. Japanese.

PMID:
24291997

Supplemental Content

Loading ...
Support Center